Bitcoin surged to $81,000, triggering the liquidation of $380 million worth of short positions within just one hour. This rapid price increase affected over 115,000 traders over a 24-hour period, highlighting significant market volatility. The hourly liquidation value and the daily trader count reflect different time frames but both indicate strong market activity. This event underscores Bitcoin's potential for sharp price moves and the risks of short selling in volatile markets.
Bitcoin's surge to $81,000 triggered $380 million in short liquidations, a striking figure illustrating intense market activity. For readers following cryptocurrency markets, here is Pluang's snapshot as of Nov 05, 2026 16:21 WIB: out of 50 major cryptocurrencies, 41 rose and 8 fell. Notable movers include ATOM at Rp27.833 (+7.39%), ALGO at Rp1.815 (+7.02%), and CAKE at Rp36.405 (+5.61%).
Wolters Kluwer repurchased 499 of its ordinary shares between October 29 and November 4, 2026, spending €0.04 million at an average price of €85.06 per share. This is part of a larger 2026 share buyback program aiming to repurchase shares worth up to...
Lorenz Snacks has introduced a fleet of four autonomous, electric vehicles from Einride at its production site in Neunburg vorm Wald, Germany. These vehicles will handle in-plant transport of goods and materials, replacing diesel trucks and significa...
Futu Holdings Limited will announce its financial results for the third quarter ending September 30, 2026, on November 19 before U.S. market open. The company will host a live earnings conference call at 7:30 AM ET (8:30 PM Beijing/Hong Kong time) th...
UBS Group AG notified Bang & Olufsen A/S that its shareholding and voting rights exceeded 5% as of October 30, 2026, but fell below 5% by November 2, 2026. As of November 2, UBS held 4.66% of Bang & Olufsen's total shares and voting rights. This chan...
T-Therapeutics secured $133 million in an oversubscribed Series B funding round led by Advent Life Sciences and British Business Bank to develop its first-in-class TCR-CD3 bispecific therapies targeting cancer and autoimmune diseases. The funds will ...
